Quick Verdict
The Achieve Life Sciences Q2 2026 Earnings report drew attention as Achieve reported a GAAP loss per share of $0.80 on zero revenue in Q2 2026, missing the $0.16 consensus loss estimate. Shares edged 0.3% lower after hours as investors weighed a $48.7 million non-cash warrant revaluation against $187.3 million cash, Q4 resubmission plans, and a potential 2027 launch.
About Achieve Life Sciences
Achieve Life Sciences, Inc. (Nasdaq: ACHV) is a late-stage specialty pharmaceutical company founded in 1991 and headquartered in Bothell, Washington, with operations also in Vancouver, British Columbia. The company is developing cytisinicline, a plant-derived alkaloid intended to support smoking cessation and nicotine e-cigarette cessation. Its immediate investment case remains centered on FDA approval, manufacturing readiness, and commercialization of a single core product candidate rather than near-term product revenue.
As of August 10, 2026, ACHV’s reported market capitalization was approximately $684 million. The company is pre-revenue and loss-making, so P/E and dividend yield are not meaningful metrics. Its Q2 financing substantially strengthened reported liquidity, although the balance sheet also carried a $183.4 million warrant and pre-funded warrant liability at June 30.
Top Financial Highlights
- GAAP net loss: $74.8 million, compared with a $12.7 million net loss in Q2 2025.
- GAAP loss per share: $0.80, versus $0.37 in Q2 2025.
- Total operating expenses: $18.4 million, up from $12.6 million a year earlier.
- Research and development expense: $3.8 million, down from $6.7 million in Q2 2025.
- General and administrative expense: $14.6 million, up from $5.9 million in the prior-year quarter.
- Other expense: $56.4 million, principally reflecting a $48.7 million non-cash change in the fair value of warrant liabilities.
- Cash, cash equivalents, and marketable securities: $187.3 million at June 30, 2026, versus $36.4 million at December 31, 2025.
- Operating cash flow: Q2 cash flow was not separately disclosed in the earnings release; cash used in operating activities was $17.7 million for the first six months of 2026.
- Gross margin: N/A, because Achieve remains pre-commercial and reported no product revenue.
- Private placement: Closed financing of up to $354 million, including $180 million upfront and up to $174 million from milestone-based warrants.
- Regulatory guidance: The company plans to resubmit its cytisinicline NDA in Q4 2026, with potential FDA approval anticipated in H1 2027 and a subsequent U.S. launch.
Consolidated Financial Statements
(Source: ir.achievelifesciences.com)
- Achieve Life Sciences’ consolidated balance sheet shows a significant expansion in both assets and liabilities during the first half of 2026. Total assets increased to USD 190.4 million as of June 30, 2026, compared with USD 41.8 million at December 31, 2025.
- The increase was primarily driven by stronger liquidity and investment holdings. Cash and cash equivalents rose to USD 48.0 million from USD 20.9 million, while marketable securities increased sharply to USD 139.3 million from USD 15.5 million. As a result, total current assets reached USD 188.3 million, accounting for almost all of the company’s asset base. Other long-term assets remained relatively limited, including USD 1.0 million of goodwill and USD 0.6 million related to the license agreement.
- On the liability side, total liabilities increased substantially to USD 205.1 million, compared with USD 20.3 million at year-end 2025. This increase was largely associated with a USD 182.7 million warrant liability, which became the largest single balance-sheet obligation. Total current liabilities consequently increased to USD 197.7 million, compared with only USD 9.1 million at December 2025. The current portion of convertible debt also rose to USD 7.5 million, while the non-current portion declined to USD 7.5 million from USD 11.2 million, indicating a greater proportion of debt becoming current.
- Stockholders’ equity moved into a negative position of USD 14.7 million, compared with positive equity of USD 21.5 million at the end of 2025. Although additional paid-in capital increased significantly to USD 330.4 million, the accumulated deficit widened to USD 345.2 million, compared with USD 260.2 million previously.
- Overall, the balance sheet indicates that Achieve Life Sciences strengthened its cash and marketable securities position considerably, but the increase in current liabilities was even more substantial. The emergence of the large warrant liability and the widening accumulated deficit resulted in negative stockholders’ equity, making liability management and future capital requirements important areas to monitor despite the stronger liquidity position.
Beat or Miss?
| Metric | Reported | Difference/Analysis |
| GAAP EPS | ($0.80) | Missed the reported consensus estimate of ($0.16) by ($0.64) per share. |
| Revenue | $0 | No reported analyst revenue estimate; the company remains pre-revenue. |
| Net loss | ($74.8 million) | Loss widened sharply year over year, primarily due to the non-cash warrant revaluation and higher G&A investment. |
| Operating expenses | $18.4 million | Increased 46.4% year over year as Achieve expanded commercial, CMC, quality, and corporate capabilities. |
| Cash and securities | $187.3 million | Strongly increased from year-end following the private placement, supporting planned regulatory, clinical, and commercial activities. |
What Leadership Is Saying
“This quarter was about building Achieve to match the significant opportunity of cytisinicline. We added a commercial team, senior CMC and quality leadership, six new directors, and advanced the finished drug product manufacturing transition to the United States.” — Andrew D. Goldberg, MD, Chief Executive Officer.
“With the team and financing in place, our focus turns to resubmission and commercial readiness. Behind that work are millions of adults still looking for help to quit.” — Andrew D. Goldberg, MD, Chief Executive Officer.
The August 11 release did not include a distinct quotation from a CFO. Jeffrey Farrow was appointed to the board and is identified as CFO and CSO of Tarsus Pharmaceuticals, rather than as Achieve’s CFO; assigning him an Achieve financial-management quote would therefore be inaccurate.
Historical Performance
| Category | Q2 2026 | Q2 2025 | Change (%) |
| Net loss | ($74.8 million) | ($12.7 million) | 489.0% wider loss. |
| Operating expenses | $18.4 million | $12.6 million | 46.4% increase. |
| R&D expense | $3.8 million | $6.7 million | 43.2% decrease. |
| G&A expense | $14.6 million | $5.9 million | 149.0% increase. |
| Basic and diluted EPS | ($0.80) | ($0.37) | 116.2% wider loss per share. |
How the Market Reacted?
ACHV closed August 11 at $6.77, up 1.5% during regular trading. In extended trading, shares were $6.75, down 0.3% as of 7:57 p.m. ET. The reaction suggests that the market viewed the strengthened cash position and path toward a Q4 NDA resubmission constructively, but remained cautious about the larger-than-expected GAAP loss and FDA-related execution risk.
Sources
